| abstract |
The present disclosure includes purine compounds of compounds of formula (I) or formula (II), or tautomers, polymorphs, stereoisomers, solvates or pharmaceutically acceptable salts thereof, or the like It relates to pharmaceutical compositions and methods for treating conditions and diseases mediated by A2B adenosine receptors as A2B adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that can be ameliorated by adenosine A2B receptor mediation. Such conditions include, but are not limited to, asthma, chronic obstructive pulmonary injury, angiogenesis, pulmonary fibrosis, emphysema, allergic disease, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis , Hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal disorders (including inflammatory bowel disease), sickle cell disease, and / or autoimmune diseases. In addition, the present disclosure addresses these in the treatment of various pathological conditions (such as digestive disorders, immune disorders, hypersensitivity disorders, neurological disorders, and cardiovascular diseases) resulting from both cellular hyperproliferation and apoptosis in mammals. Regarding use. The present disclosure also relates to methods for preparing such compounds, and pharmaceutical compositions containing them. |